Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Yohei Otake"'
1
Akademický článek
Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort
Autor: Takashi Oshima, Sachiko Yamamoto, Hisato Kawakami, Tomoki Makino, Akihito Kawazoe, Toshiki Masuishi, Takahiro Tsushima, Motohiro Hirao, Masahiro Tsuda, Kaori Hino, Noboru Yamamoto, Hiroki Hara, Shota Kaname, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Akira Ooki
Publikováno v: BJC Reports, Vol 2, Iss 1, Pp 1-7 (2024)
Abstract Background Esophageal cancer is one of the most common types of cancer in Japan. Herein, we report the efficacy and safety of E7389-LF plus the immune checkpoint inhibitor, nivolumab, from the esophageal cancer cohort of the phase 2 part of
Externí odkaz: https://doaj.org/article/7dbdc5c5725f466f9c680a126d352047
Zobrazit plný text záznamu
3
The esophageal cancer cohort of a phase 2 trial of E7389-LF (liposomal formulation of eribulin) + nivolumab
Autor: Akira Ooki, Sachiko Yamamoto, Hisato Kawakami, Tomoki Makino, Akihito Kawazoe, Toshiki Masuishi, Takahiro Tsushima, Motohiro Hirao, Naoki Takegawa, Kaori Hino, Satoru Iwasa, Hiroki Hara, Naoki Sumiyoshi, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Takashi Oshima
Publikováno v: Journal of Clinical Oncology. 41:337-337
337 Background: E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor, eribulin. Treatment with E7389-LF plus the programmed cell death 1 inhibitor nivolumab may result in an increased antitumor effect through vascular remodeling.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9d78064ece89724a00c157f7fa56a173
https://doi.org/10.1200/jco.2023.41.4_suppl.337
Zobrazit plný text záznamu
4
Gastric cancer (GC) cohort of a phase 2 trial of E7389-LF (liposomal formulation of eribulin) in combination with nivolumab
Autor: Kei Muro, Satoru Iwasa, Naotoshi Sugimoto, Hisato Kawakami, Takashi Oshima, Kensei Yamaguchi, Kaori Hino, Motohiro Hirao, Yukinori Kurokawa, Takeshi Kawakami, Naoki Takegawa, Hiroki Hara, Naoki Sumiyoshi, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Akihito Kawazoe
Publikováno v: Journal of Clinical Oncology. 41:339-339
339 Background: Due to a lack of efficacy and long-term survival seen in previously-studied therapies, new therapies for pretreated advanced GC are warranted. E7389-LF is a new formulation that uses liposomes to encapsulate eribulin; this is anticipa
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7a4a755b672546407d4f39ef32353e5e
https://doi.org/10.1200/jco.2023.41.4_suppl.339
Zobrazit plný text záznamu
5
A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma
Autor: Masamichi Takahashi, Satoshi Kawashima, Yohei Otake, Natsuko Satomi-Tsushita, Aya Kuchiba, Ryo Sadachi, Keiko Ohata, Hitoshi Ozawa, Kan Yonemori, Motoo Nagane, Yoshiki Arakawa, Akitake Mukasa, Shota Tanaka, Ryo Nishikawa, Yoshihiro Muragaki, Kenkichi Masutomi, Koichi Ichimura, Kenichi Nakamura, Yoshitaka Narita
Publikováno v: Journal of Clinical Oncology. 40:2036-2036
2036 Background: Glioblastoma (GBM) is one of the worst prognostic cancers and there is no effective treatment after failure of bevacizumab. Eribulin is a microtubule inhibitor used for the treatment of patients with metastatic breast cancer and lipo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::71a80b130a66109ef9bc5da42944a46a
https://doi.org/10.1200/jco.2022.40.16_suppl.2036
Zobrazit plný text záznamu
6
Safety and efficacy of MORAb-202 in patients (pts) with platinum-resistant ovarian cancer (PROC): Results from the expansion part of a phase 1 trial
Autor: Shin Nishio, Mayu Yunokawa, Koji Matsumoto, Kazuhiro Takehara, Kosei Hasegawa, Yasuyuki Hirashima, Hidenori Kato, Hiroki Ikezawa, Maiko Nomoto, Seiichi Hayato, Yohei Otake, Takuma Miura, Kan Yonemori
Publikováno v: Journal of Clinical Oncology. 40:5513-5513
5513 Background: MORAb-202 is an antibody-drug conjugate consisting of farletuzumab (an antibody that binds to folate receptor alpha [FRα]) paired with eribulin mesylate (a microtubule dynamics inhibitor) conjugated via a cathepsin-B–cleavable lin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2278c727c09af4c73365cf90a890eb2
https://doi.org/10.1200/jco.2022.40.16_suppl.5513
Zobrazit plný text záznamu
8
Liquid Flow and Mixing in Bottom Regions of Baffled and Unbaffled Vessels Agitated by Turbine-Type Impeller
Autor: Naoki Shimada, Masanori Yoshida, Yohei Otake, Rei Kanno, Satoshi Matsuura
Publikováno v: International Journal of Chemical Reactor Engineering. 12:629-638
For a vessel agitated by the turbine-type impeller, the liquid flow and mixing in the bottom region were studied for comparison between conditions with and without baffles. Visualization of the flow and its measurement were done using particle tracki
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e589d0054786cd9b76347ce136108b0c
https://doi.org/10.1515/ijcre-2014-0086
Zobrazit plný text záznamu
9
A rumor transmission model with various contact interactions
Autor: Hiraku Yoshida, Yohei Otake, Katsuhide Warashina, Hiroshi Ueda, Motohide Seki, Kazuki Kawachi
Publikováno v: Journal of theoretical biology. 253(1)
We consider a rumor transmission model with various contact interactions and explore what effect such interactions have on the spread of a rumor, in particular whether they can explain the rumor recursion. Through mathematical analysis and computer s
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b80561e56a1a893b37cb09cfb42ff70
https://pubmed.ncbi.nlm.nih.gov/18179802
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje